Podcasts about crispr cas9

From baby blood to breakthrough cures — we explore how unlocking fetal hemoglobin through gene editing (exa-cel/Casgevy) is transforming treatment for sickle cell disease and β-thalassemia.

Viele Dinge werden zwischen Lebewesen oder Pflanzen vererbt. Mit einer Genschere wie CRISPR/CAS9 könnte man in das Erbmaterial eingreifen. Kompliziert aber revolutionär.

This week we talk about gene-editing, CRISPR/Cas9, and ammonia.We also discuss the germ line, mad scientists, and science research funding.Recommended Book: The Siren's Call by Chris HayesTranscriptBack in November of 2018, a Chinese scientist named He Jiankui achieved global notoriety by announcing that he had used a relatively new gene-editing technique on human embryos, which led to the birth of the world's first gene-edited babies.His ambition was to help people with HIV-related fertility problems, one of which is that if a parent is HIV positive, there's a chance they could transmit HIV to their child.This genetic modification was meant to confer immunity to HIV to the children so that wouldn't be an issue. And in order to accomplish that immunity, He used a technology called CRISPR/Cas9 to modify the embryos' DNA to remove their CCR5 gene, which is related to immune system function, but relevant to this undertaking, also serves as a common pathway for the HIV-1 virus, allowing it to infect a new host.CRISPR is an acronym that stands for clustered regularly interspaced short palindromic repeats, and that refers to a type of DNA sequence found in all sorts of genomes, including about half of all sequenced bacterial genomes and just shy of 90% of all sequenced archaea genomes.Cas9 stands for CRISPR-associated protein 9, which is an enzyme that uses CRISPR sequences, those repeating, common sequences in DNA strands, to open up targeted DNA strands—and when paired with specific CRISPR sequences, this duo can search for selected patterns in DNA and then edit those patterns.This tool, then, allows researchers who know the DNA pattern representing a particular genetic trait—a trait that moderates an immune system protein that also happens to serve as a convenient pathway for HIV, for instance—to alter or eliminate that trait. A shorthand and incomplete way of thinking about this tool is as a sort of find and replace tool like you have in a text document on your computer, and in this instance, the gene sequence being replaced is a DNA strand that causes a trait that in turn leads to HIV susceptibility.So that's what He targeted in those embryos, and the children those embryos eventually became, who are usually referred to as Lulu and Nana, which are pseudonyms, for their privacy, they were the first gene-edited babies; though because of the gene-editing state of the art at the time, while He intended to render these babies' CCR5 gene entirely nonfunctional, which would replicate a natural mutation that's been noted in some non-gene-edited people, including the so-called Berlin Patient, who was a patient in Germany in the late-90s who was functionally cured of HIV—the first known person to be thus cured—while that's what He intended to do, instead these two babies actually carry both a functional and a mutant copy of CCR5, not just the mutant one, which in theory means they're not immune to HIV, as intended.Regardless of that outcome, which may be less impactful than He and other proponents of this technology may have hoped, He achieved superstardom, briefly, even being named one of the most influential people in the world by Time magazine in 2019. But he was also crushed by controversy, stripped of his license to conduct medical research by the Chinese government, sent to prison for three years and fined 3 million yuan, which is more than $400,000, and generally outcast from the global scientific community for ethical violations, mostly because the type of gene-editing he did wasn't a one-off sort of thing, it was what's called germ-line editing, which means those changes won't just impact Lulu and Nana, they'll be passed on to their children, as well, and their children's children, and so on.And the ethical implications of germ-line editing are so much more substantial because while a one-off error would be devastating to the person who suffers it, such an error that is passed on to potentially endless future generations could, conceivably, end humanity.The error doesn't even have to be a botched job, it could be an edit that makes the edited child taller or more intelligent by some measure, or more resistant to a disease, like HIV—but because this is fringy science and we don't fully understand how changing one thing might change other things, the implications for such edits are massive.Giving someone an immunity to HIV would theoretically be a good thing, then, but if that edit then went on the market and became common, we might see a generation of humans that are immune to HIV, but potentially more susceptible to something else, or maybe who live shorter lives, or maybe who create a subsequent generation who themselves are prone to all sorts of issues we couldn't possibly have foreseen, because we made these edits without first mapping all possible implications of making that genetic tweak, and we did so in such a way that those edits would persist throughout the generations.What I'd like to talk about today is another example of a similar technology, but one that's distinct enough, and which carries substantially less long-term risk, that it's being greeted primarily with celebration rather than concern.—In early August of 2024, a gene-editing researcher at the University of Pennsylvania, Dr. Kiran Musunuru, was asked if there was anything he could do to help a baby that was being treated at the Children's Hospital of Philadelphia for CPS1 deficiency, which manifests as an inability to get rid of the ammonia that builds up in one's body as a byproduct of protein metabolism.We all generate a small amount of ammonia just as a function of living, and this deficiency kept the baby from processing and discarding that ammonia in the usual fashion. As a result, ammonia was building up in its blood and crossing into its brain.The usual method of dealing with this deficiency is severely restricting the suffer's protein intake so that less ammonia is generated, but being a baby, that meant it wasn't able to grow; he was getting just enough protein to survive and was in the 7th percentile for body weight.So a doctor at the Children's Hospital wanted to see if there was anything this gene-editing researcher could do to help this baby, who was at risk of severe brain damage or death because of this condition he was born with.Gene-editing is still a very new technology, and CRISPR and associated technologies are even newer, still often resulting in inaccurate edits, many of which eventually go away, but that also means the intended edit sometimes goes away over time, too—the body's processes eventually replacing the edited code with the original.That said, these researchers, working with other researchers at institutions around the world, though mostly in the US, were able to rush a usually very cumbersome and time-consuming process that would typically take nearly a decade, and came up with and tested a gene-editing approach to target the specific mutation that was causing this baby's problems, and they did it in record time: the original email asking if Dr Musunuru might be able to help arrived in August of 2024, and in late-February of 2025, the baby received his first infusion of the substance that would make the proper edits to his genes; they divided the full, intended treatment into three doses, the first being very small, because they didn't know how the baby would respond to it, and they wanted to be very, very cautious.There were positive signs within the first few weeks, so 22 days later, they administered the second dose, and the third followed after that.Now the research and medical worlds are waiting to see if the treatment sticks; the baby is already up to the 40th percentile in terms of weight for his age, is able to eat a lot more protein and is taking far less medication to help him deal with ammonia buildup, but there's a chance that he may still need a liver transplant, that there might be unforeseen consequences due to that intended edit, or other, accidental edits made by the treatment, or, again, that the edits won't stick, as has been the case in some previous trials.Already this is being heralded as a big success, though, as the treatment seems to be at least partially successful, hasn't triggered any serious, negative consequences, and has stuck around for a while—so even if further treatments are needed to keep the gene edited, there's a chance this could lead to better and better gene-editing treatments in the future, or that such treatments could replace some medications, or be used for conditions that don't have reliable medications in the first place.This is also the first known case of a human of any age being given a custom gene-editing treatment (made especially for them, rather than being made to broadly serve any patient with a given ailment or condition), and in some circles that's considered to be the future of this field, as individually tailored gene-treatments could help folks deal with chronic illnesses and genetic conditions (like cystic fibrosis, Huntington's disease, muscular dystrophy, and sickle cell), but also possibly help fight cancers and similar issues.More immediately, if this treatment is shown to be long-term efficacious for this first, baby patient, it could be applied to other patients who suffer the same deficiency, which afflicts an estimated 1 in 1.3 million people, globally. It's not common then—both parents have to have a mutant copy of a specific gene for their child to have this condition—but that's another reason this type of treatment is considered to be promising: many conditions aren't widespread enough to justify investment in pharmaceuticals or other medical interventions that would help them, so custom-tailored gene-editing could be used, instead, on a case-by-case basis.This is especially true if the speed at which a customized treatment can be developed is sped-up even further, though there are concerns about the future of this field and researchers' ability to up its efficiency as, at least in the US, the current administration's gutting of federal research bodies and funding looks likely to hit this space hard, and previous, similar victories that involved dramatically truncating otherwise ponderous developmental processes—like the historically rapid development of early COVID-19 vaccines—are not looked at favorably by a larger portion of the US electorate, which could mean those in charge of allocating resources and clearing the way for such research might instead pull even more funding and put more roadblocks in place, hobbling those future efforts, rather than the opposite.There are plenty of other researchers and institutions working on similar things around the world, of course, but this particular wing of that larger field may have higher hurdles to leap to get anything done in the coming years, if current trends continue.Again, though, however that larger context evolves, we're still in the early days of this, and there's a chance that this approach will turn out to be non-ideal for all sorts of reasons.The concept of tailored gene-editing therapies is an appealing one, though, as it could replace many existing pharmaceutical, surgical, and similar approaches to dealing with chronic, inherited conditions in particular, and because it could in theory at least allow us to address such issues rapidly, and without needing to mess around with the germ-line, because mutations could be assessed and addressed on a person-by-person basis, those edits staying within their bodies and not being passed on to their offspring, rather than attempting to make genetic customizations for future generations based on the imperfect knowledge and know-how of today's science, and the biased standards and priorities of today's cultural context.Show Noteshttps://www.nejm.org/doi/full/10.1056/NEJMoa2504747https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatmenthttps://www.wired.com/story/a-baby-received-a-custom-crispr-treatment-in-record-time/https://www.wsj.com/tech/biotech/crispr-gene-editing-therapy-philadelphia-infant-8fc3a2c5https://www.washingtonpost.com/science/2025/05/15/crispr-gene-editing-breakthrough/https://www.npr.org/sections/shots-health-news/2025/05/15/nx-s1-5389620/gene-editing-treatment-crispr-inheritedhttps://interestingengineering.com/health/first-personalized-crispr-gene-therapyhttps://www.nature.com/articles/d41586-025-01496-zhttps://www.nytimes.com/2025/05/15/health/gene-editing-personalized-rare-disorders.htmlhttps://www.nytimes.com/2025/05/31/world/asia/us-science-cuts.htmlhttps://www.livescience.com/health/genetics/us-baby-receives-first-ever-customized-crispr-treatment-for-genetic-diseasehttps://en.wikipedia.org/wiki/He_Jiankui_affairhttps://en.wikipedia.org/wiki/CCR5https://en.wikipedia.org/wiki/Berlin_Patienthttps://en.wikipedia.org/wiki/CRISPR_gene_editinghttps://en.wikipedia.org/wiki/CRISPRhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6813942/ This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

First, we talk to The Indian Express' National Education Editor Ritika Chopra about the CBSE asking its affiliate schools to map students' mother tongues at the earliest, and prepare teaching materials before the end of the summer break. This is being done to eventually make instructions in students' mother tongue mandatory in schools at the primary level.Next, we talk to The Indian Express' Alind Chauhan who breaks down a major scientific breakthrough for us. He talks about CRISPR-Cas9, a custom gene-editing tool that can become a solution for many genetic disorders. He also shares how an extended version of this technology helped a nine month old baby with a rare genetic condition. (14:03)Lastly, we discuss what Chief of Defence Staff General Anil Chauhan had to say about India's losses in Operation Sindoor. (25:43)Hosted by Niharika NandaProduced and written by Niharika Nanda and Shashank Bhargava.Edited and mixed by Suresh Pawar

In this episode of the Epigenetics Podcast, we talked with Ani Deshpande from Sanford Burnham Prebys about his work on epigenetic regulation and developing small molecules through high throughput screens for AML. Throughout our discussion, we delve into Dr. Despande's journey into the field of biology and science, tracing his evolution from a literature enthusiast in Mumbai to a dedicated cancer researcher. He reflects on his formative experiences during his PhD at Ludwig Maximilian University in Munich, where she developed murine models for refractory acute myeloid leukemia (AML). We examine these models' contributions to therapeutic discovery and understanding the intricate mechanisms underscoring AML's complexities. Transitioning to his postdoctoral work at Scott Armstrong's lab in Boston, Dr. Despande shares his insights on the importance of epigenetic regulators, such as DOT1L, in leukemias, and how they can serve as strategic therapeutic targets. His ambitious pursuit of translational research is further highlighted through his efforts in developing a conditional knockout mouse model and his collaborative work utilizing CRISPR technology to refine our understanding of epigenetic regulation in cancer pathogenesis. Moreover, we engage in a conversation about the challenges and opportunities that arise when establishing his lab at Sanford Burnham Prebys. Dr. Despande candidly discusses the delicate balance between pursuing topics of genuine interest versus adhering to grant fundability, underlining the tension researchers face in the current scientific landscape. His emphasis on the critical need for innovation within lab settings serves as a motivational call for emerging scientists to venture beyond the established templates that often inhibit groundbreaking discoveries. We conclude our dialogue with an exploration of his recent projects, which involve targeting specific epigenetic modifiers and how his lab's findings can contribute to greater understanding and potential treatments for not only AML but also other pediatric cancers driven by gene fusions. Dr. Despande's insights into the integration of modern technologies, such as CRISPR libraries, exemplify his commitment to pushing the boundaries of cancer research. In addition to discussing his scientific contributions, we touch upon Dr. Despande's foray into podcasting (The Discovery Dialogues), shedding light on his motivation to bridge the communication gap between scientists and the broader public. He articulates his desire to demystify scientific discoveries and promote awareness about the intricate journey of research that lays the groundwork for medical advancements. This multidimensional discussion not only highlights his scientific achievements but also emphasizes the importance of effective science communication in fostering public understanding and appreciation of research.   References Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig WD, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006 Nov;10(5):363-74. doi: 10.1016/j.ccr.2006.08.023. PMID: 17097559. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014 Dec 8;26(6):896-908. doi: 10.1016/j.ccell.2014.10.009. Epub 2014 Nov 20. PMID: 25464900; PMCID: PMC4291116. Sinha S, Barbosa K, Cheng K, Leiserson MDM, Jain P, Deshpande A, Wilson DM 3rd, Ryan BM, Luo J, Ronai ZA, Lee JS, Deshpande AJ, Ruppin E. A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. Nat Commun. 2021 Nov 11;12(1):6512. doi: 10.1038/s41467-021-26788-6. Erratum in: Nat Commun. 2022 May 16;13(1):2828. doi: 10.1038/s41467-022-30475-5. PMID: 34764240; PMCID: PMC8586238.   Related Episodes Targeting COMPASS to Cure Childhood Leukemia (Ali Shilatifard) The Menin-MLL Complex and Small Molecule Inhibitors (Yadira Soto-Feliciano) MLL Proteins in Mixed-Lineage Leukemia (Yali Dou)   Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

En octubre del año pasado nacieron Rómulo y Remo. Dos lobos. Hasta ahí no hay discusión. La polémica se abrió cuando la empresa que los creó, Colossal Biosciences, de Estados Unidos, anunció que eran lobos gigantes desextinguidos en base a ADN de restos fósiles y edición genética. Esta compañía privada de biotecnología, valuada en unos 10.200 millones de dólares, “produjo” a los dos lobitos en base a una técnica de edición genética llamada Crispr-Cas9. Unos meses se sumó una tercera integrante de la manada, llamada Khaleesi. Collossal sostiene que son lobos gigantes, que logró su desextinción después de 10.000 años de que esos animales no pisaran el planeta Tierra y muchos medios del mundo también lo comunicaron de ese modo. El marketing y los clicks se fueron a las nubes, pero pasan los días y crecen las voces que contradicen estas afirmaciones. “Son lobos grises modificados”. “Son lobos grises tuneados”. “Es imposible la desextinción de especies”. Estas son frases de científicos que, alrededor del mundo, contradicen a Colossal Bioscience y dan sus razones técnicas. Pero a eso se suma otro factor: el ético. ¿Es correcto “revivir” especies extintas? ¿Cómo impacta esto en el mundo, en la biodiversidad e incluso en los humanos? ¿Acaso estamos jugando a ser dioses? Los invitamos a entrar en este mundo apasionante del llamado lobo gigante, que desextinguido o no, seguro no deja a nadie indiferente. En La Mesa de Científicos buceamos en este tema junto a dos científicos, un filósofo y una especialista en periodismo científico: Juan Pablo Tosar, Daniela Hirschfeld, Javier Mazza y nuestro locatario, coordinador de las mesas de científicos, Héctor Musto.

Cancer is a daunting healthcare challenge, and is still affecting millions worldwide, despite the enormous research resources that have been directed at finding effective treatments over the past decades. Many anti-cancer treatments remain poorly specific for the tumours they are intended to treat, and often suffer from modest efficacy and serious off-target effects. Part of the problem is the inherent variability between many tumours and their resulting unpredictable responses to standard chemotherapy. However, the latest advancements in precision oncology may be the start of a new paradigm, potentially providing targeted therapeutic payloads that can successfully address the specific and unique issues underlying a given patient's cancer. Researchers such as Prof. Diana Jaalouk and her colleagues at the American University of Beirut in Lebanon are pioneering innovative tools that are changing the way we understand and treat this complex disease. Two remarkable recent technologies, CRISPR-Cas9 and PROteolysis TArgeting Chimeras (or PROTACs for short), are at the forefront of this precision revolution. While distinct in their approach, these tools share a common goal: targeting cancer with precision and minimizing harm to healthy cells. Together, they are set to reshape the therapeutic landscape.

Scientific discovery happens in the lab—but it starts with curiosity and determination. In this episode of Absolute Gene-ius, we welcome Valeria Rangel, a PhD candidate at the University of California Irvine, who shares her research on acute lymphoblastic leukemia and the innovative ways digital PCR is helping uncover genetic patterns linked to cancer in Hispanic populations.Val's work focuses on Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia, a rare and aggressive form of cancer. She explains how her lab uses digital PCR to detect mutations with high precision, identify risk factors in certain populations, and even validate findings using CRISPR-Cas9 gene editing. Through her research, Val sheds light on the role of SNPs, methylation patterns, and translocations in leukemia progression—demonstrating how digital PCR is transforming the way we approach cancer research.Beyond the science, Val takes us on her personal journey, from struggling to break into research due to financial barriers to finding her passion in oncology. In this episode's Career Corner, she shares valuable advice for aspiring scientists, tips for landing research opportunities, and some of her most hilarious and humbling lab moments (yes, she has broken multiple pipettes).Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

★ Unterstützt den Podcast via Patreon und erhaltet exklusive Bonusfolgen ★---Holt euch das Buch: CRISPR/Cas9 Einschneidende Revolution in der GentechnikDas CRISPR/Cas9 ist eine Revolution der modernen Gen-Technik und in dieser Folge schauen wir uns an, was genau dahinter steckt. In ihrem Buch "CRISPR/Cas9 Einschneidende Revolution in der Gentechnik" stellen die beiden Wissenschaftsautoren Toni Cathomen und Holger Puchta eine Sammlung aus verschiedenen Peer-Reviewten Artikeln vor und ordnen diese ein. Das alles doch nicht so heiß gegessen wird wie man es kocht und wieso wir vielleicht doch noch etwas von dem "Mensch auf Rezept" entfernt sind, erfahrt ihr in dieser Folge. Shownotes wie immer unter swpodcast.de---Schwarz auf Weiß Rating:Quellen Dichte F 4/5 & S 4/5Verständlichkeit F 5/5 & S 5/5Umsetzbarkeit F 0/5 & S 0/5Würde ich weiterempfehlen?  F Nein & S Nein---Feedback, Wünsche und Beschimpfungen könnt ihr uns per Email schicken: feedback@swpodcast.deDu willst mehr lesen und dich mit Gleichgesinnten austauschen? Dann komm in unseren SW Podcast Buchclub Hosted on Acast. See acast.com/privacy for more information.

Maria shares insights into the concerning reality of the transhumanist agenda being actively pursued by governments and corporations. She explains that transhumanism, often dismissed as conspiracy, is in fact a very real and alarming movement with tangible plans to reshape humanity. Through her meticulous microscopic research, Maria uncovers disturbing evidence of contaminants and foreign materials in COVID-19 vaccines, suggesting a sinister agenda beyond just public health She cautions that this information should be approached carefully, as those revealing these truths have faced serious consequences. Maria's work aims to empower people with knowledge to make informed decisions and take action against this emerging threat to our humanity. According to the speaker, we are in the midst of a concerning transition that humanity did not ask for The speaker believes there is a concerted effort to transform and harvest humans, as evidenced by the introduction of inorganic blood contaminants and other threats to our health and well-being. The speaker urges the audience to be vigilant and resist these efforts, as the human body and genome are incredible and worth preserving. They raise alarming questions about population declines, poisoning, and the emergence of different human species, calling for action to break free from this biological and spiritual battle The speaker discusses the alarming capabilities of nanoparticles and microrobots, which can be programmed for surveillance, drug delivery, and even self-replication using DNA. They warn that these advanced technologies, which can interface with mobile phones and satellites, are already being deployed and can monitor individuals from within their own bodies. The speaker emphasizes the complex physics behind these particles, their ability to adapt to environmental factors, and the potential dangers they pose to unsuspecting individuals The speakers discuss the use of silicone-encapsulated nanoparticles and hydrogels in various medical and scientific applications. These include gene editing with CRISPR-Cas9, tracking genetically engineered microorganisms, delivering growth factors for tissue engineering, and creating biosensing platforms. The speakers highlight the complexity of these materials and the importance of understanding how they interact with the human body They caution about the potential risks and emphasize the need for thorough testing and evaluation to ensure the safety and efficacy of these emerging technologies. The speaker discusses their research into nanoparticles and bioengineered materials that appear to be self-replicating and overwhelming people's immune systems. They describe seeing fibers, hydrogels, and other complex structures forming, and how these substances can integrate with the body in harmful ways, leading to organ damage and the surge of certain cancers The speaker also raises concerns about a "Florida fog" that contained toxic chemicals like platinum and styrene, making people sick. They emphasize the importance of understanding these emerging threats to public health and the need to find ways to eliminate these dangerous particles from the body. The speaker discusses their concerns about chemicals potentially being dispersed through atmospheric phenomena like fog They describe analyzing samples and finding high levels of metals like platinum, as well as compounds like polyethylene glycol that are used in various technologies. The speaker believes these elements may be intentionally introduced to increase reaction rates and yields for certain processes. They also note concerning health effects like muscle weakness that can arise from exposure to these substances Overall, the speaker is deeply worried about the potential impacts of these mysterious dispersed materials on people's health and the environment. The speaker shares their concerning observations about changes in weather patterns and the presence of unusual particles and fibers in snow and blood samples. They describe finding substances like thallium, platinum, yttrium, silicone, and bromine, as well as fiber-like structures that appear to be tethering white blood cells together The speaker suggests these fibers may be part of a "synthetic biology" system that is harvesting electrons and disrupting the electrical charge of the blood. They express alarm at these findings and their potential implications for human health. The speakers discuss the concerning presence of synthetic materials, such as silicone, platinum, and tellurium, in human blood samples, both injected and uninjected They describe how these materials can form fiber-like structures that become superconductive, potentially allowing them to take over the body. The speakers warn that this proliferation of synthetic materials is happening regardless of whether someone has received injections, and that eventually the body will become overwhelmed. They emphasize the need to understand how these materials are using our biology against us, highlighting the role of chlorine in the white blood cell response as particularly important The speaker describes their shocking discovery of what they call "Hydra" - a complex, multi-material structure that grew within the blood of a person who had received two Pfizer vaccine doses. The speaker expresses fear and concern over the apparent indestructibility of this structure, which they believe is part of a broader phenomenon of strange fibrous formations appearing in people's blood and bodily fluids post-vaccination. The speaker emphasizes the need to proactively detoxify the body, particularly through infrared saunas and lymphatic drainage, in order to eliminate the silicone and other metals that seem to be accumulating in the body Overall, the speaker shares a deeply troubling finding that they believe warrants urgent investigation and action. The speakers delve into the concerning issue of geoengineering and the contamination of our environment with synthetic materials like silicone, bromine, tellurium, and zirconium. These nanoparticles are found in our food, water, soil, and air, and can severely impact our health, causing inflammation, DNA damage, and organ toxicity The speakers emphasize the need to understand how these materials interact with electromagnetic fields and are used in various technologies, from biosensors to soft robotics. They urge the audience to be aware of the far-reaching consequences of this environmental pollution and the importance of keeping these harmful substances out of our bodies. The speaker discusses the concerning implications of new technologies being introduced into the human body, such as soft robotics, silicon nanoparticles, and strontium contamination They express worries that these substances are transforming people into "transhuman entities" and causing issues like young children needing frequent blood transfusions. The speaker believes many people who have received injections may not survive long-term, as their cells become synthetic and vulnerable to diseases and parasites. Overall, the speaker paints a dystopian picture of the potential risks of these emerging technologies being integrated into the human body The speaker expresses deep concerns about a potential dystopian future where a fungal pathogen causes a mass human die-off, and survivors are either transformed into controllable "transhumans" or face shortened lifespans and social credit-based discrimination. They believe the younger generation, particularly those aged 18-30, are the primary targets. The speaker cites evidence of genome integration and parasitic infestations, warning that those who did not take the injection may be overcome by the aggressive reactivity of their biology They also believe that the spraying of substances is affecting people's minds, leading to strange and uncontrolled behaviors. The speaker advocates for maintaining one's wits and discernment in these challenging times, but remains convinced that their insights are real and true, and that the situation can be broken down and understood. The speakers discuss the challenges of removing harmful substances like lanthanides and rare earth metals from the body, which are found in vaccines and other medical products They suggest using a combination of natural and synthetic remedies, such as EDTA, methylene blue, and DMSO, to help chelate and remove these toxins. However, they caution that the process must be done carefully and in the right order, using toxin binders to prevent reaccumulation. The speakers also highlight how these metals are used in various products, including hydrogels and GMO foods, to stabilize them, making them difficult to break down They propose using enzymes like cellulase to disrupt the gel structure and remove the lanthanide hydrogels from the body. The speakers are discussing the complex science behind quantum computing, superconductors, and advanced physics used in synthetic biology. They describe the use of lanthanide-doped nanocrystals that can undergo photon upconversion, a process that generates energy in a continuous loop The speakers warn that these technologies are being used against us, potentially building neural networks inside human beings. They emphasize the dangers of these advanced physics applications and the need to understand the mechanisms involved. The speaker discusses their findings about the presence of various metals, including yttrium and thallium, in the human body and their concerning implications They explain how these metals can bind to chlorine, form hydrogels, and act as battery packs and computers within the body, potentially contributing to the development of synthetic beings. The speaker also highlights the lack of regulation and oversight in the biomedical industry's use of these nanomaterials, urging listeners to take action against the government agencies that enable this concerning practice. The speaker shares their extensive research into combating the synthetic contaminants and technological transformations that they believe are being used to control and exploit humanity They have developed a product called Novolytic, which aims to oxidize and break down harmful hydrogels, protect against DNA integration, remove synthetic and zombie cells, and prevent the formation of superconductive fibers and self-replicating nanoparticles. The speaker believes Novolytic can help people lead an asymptomatic life and feel safe, though they emphasize it is not a cure. Their goal is to resist the transformation of humanity into a "cyborg reality" and empower people to partner with their own bodies to remove these synthetic contaminants The speakers discussed a revolutionary approach to protecting telomeres, the protective caps at the ends of DNA strands. They have developed a natural supplement called Insulis that has shown the ability to not only maintain but even increase telomere length, even in individuals who have received COVID-19 vaccines. The speakers, including Dr Group of Global Healing, are partnering to manufacture and distribute this product widely to help people combat the potential negative impacts of the vaccines. Their goal is to provide a safe, natural solution that can empower people to take control of their health and fight back against synthetic threats. In this podcast dialogue, the speakers discuss groundbreaking research and innovations aimed at helping humanity One speaker, an expert in quantum hematology, believes that the rush to implement Agenda 2030 is driven by fear of human consciousness and its powerful electrical and vibrational effects. They suggest that by remediating and reconnecting with each other, and healing our gut health, we can find a way to stop the "garbage" and elevate as a race. The speakers are passionate about sharing this transformative information and encourage the audience to visit their website, Abaytonaturals com, to learn more.

Emmanuelle Ducros nous raconte une histoire digne d'un film de science-fiction. Une entreprise de biotechnologie de la Silicon Valley, Colossal Biosciences, a réussi à ressusciter une espèce de loup géant éteinte depuis 13 000 ans : le loup sinistre.Après avoir obtenu de l'ADN de cette créature disparue, l'entreprise a utilisé la technologie d'édition génomique CRISPR-Cas9 pour modifier le génome d'un loup moderne et recréer les caractéristiques du loup sinistre. Le résultat est surprenant : deux jeunes loups, Romulus et Remus, et une petite femelle nommée Khaleesi, sont aujourd'hui en vie dans une réserve tenue secrète.Mais cette prouesse technologique soulève de nombreuses questions. À quoi servent ces animaux ressuscités ? Des attractions de zoos ? Un moyen de se donner bonne conscience sur les extinctions actuelles ? Emmanuelle Ducros analyse les enjeux éthiques et les dérives potentielles de cette expérience de "Jurassic Park dans la Silicon Valley".Au-delà du loup sinistre, Colossal Biosciences envisage également de faire renaître d'autres espèces emblématiques, comme le mammouth laineux ou le dodo. Mais cette science du spectacle ne risque-t-elle pas de détourner l'attention des véritables enjeux de la préservation de la biodiversité ?Cet épisode vous invite à réfléchir sur les limites de la technologie et les dérives potentielles de l'hybris humaine. Ne manquez pas cette analyse incisive et originale de "Voyage en Absurdie" !Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Emmanuelle Ducros nous raconte une histoire digne d'un film de science-fiction. Une entreprise de biotechnologie de la Silicon Valley, Colossal Biosciences, a réussi à ressusciter une espèce de loup géant éteinte depuis 13 000 ans : le loup sinistre.Après avoir obtenu de l'ADN de cette créature disparue, l'entreprise a utilisé la technologie d'édition génomique CRISPR-Cas9 pour modifier le génome d'un loup moderne et recréer les caractéristiques du loup sinistre. Le résultat est surprenant : deux jeunes loups, Romulus et Remus, et une petite femelle nommée Khaleesi, sont aujourd'hui en vie dans une réserve tenue secrète.Mais cette prouesse technologique soulève de nombreuses questions. À quoi servent ces animaux ressuscités ? Des attractions de zoos ? Un moyen de se donner bonne conscience sur les extinctions actuelles ? Emmanuelle Ducros analyse les enjeux éthiques et les dérives potentielles de cette expérience de "Jurassic Park dans la Silicon Valley".Au-delà du loup sinistre, Colossal Biosciences envisage également de faire renaître d'autres espèces emblématiques, comme le mammouth laineux ou le dodo. Mais cette science du spectacle ne risque-t-elle pas de détourner l'attention des véritables enjeux de la préservation de la biodiversité ?Cet épisode vous invite à réfléchir sur les limites de la technologie et les dérives potentielles de l'hybris humaine. Ne manquez pas cette analyse incisive et originale de "Voyage en Absurdie" !Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Imagine your doctor could precisely predict your personal risk of disease, diagnose the cause of illness with pinpoint accuracy when it did occur, and develop an effective treatment plan with low side effects the first time, rather than through trial and error. That's the promise of personalized medicine. And it would be a revolution in healthcare. At the heart of this vision is the notion that our genetic differences have a big impact on how each of us responds to disease and treatment. To realize a future of personalized medicine then, we need to understand and investigate just how genetic variations, including mutations, contribute to illness and respond to doctors' attempts to address it. But how can scientists do that efficiently with a human genome that spans about three billion base pairs of DNA across tens of thousands of genes? That's where the work of PhD student Dawn Chen comes in. A student in Harvard's Department of Stem Cell and Regenerative Biology and the Systems, Synthetic, and Quantitative Biology Program, Chen was named a recipient of the 2025 Harold M. Weintraub Graduate Student Award for Outstanding Achievement and Exceptional Research in the Biological Sciences, presented by Seattle's Fred Hutch Cancer Center. With her colleagues in the lab of Harvard professor Fei Chen, Dawn Chen is developing an innovative gene-editing tool known as helicase-assisted continuous editing, or HACE. A breakthrough in genetic engineering, supported in part by funds from the National Institutes of Health, HACE makes edits to specific genes, allowing researchers to investigate how genetic variations contribute to disease. The technique could lead to the identification of specific mutations that influence the effectiveness of drugs and therapies for illnesses like cancer. 

Plongez dans l'univers fascinant et controversé de CRISPR-Cas9, une technique de modification génétique qui promet de révolutionner la médecine. Entre espoirs de guérison et risques éthiques, découvrez les enjeux de cette innovation révolutionnaire.La tech entre les lignes, la chronique qui décrypte les articles tech, animée par Louis de Diesbach.   ***** À PROPOS DE TRENCH TECH *****LE talkshow « Esprits Critiques pour Tech Ethique »Écoutez-nous sur toutes les plateformes de podcast

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Joseph Eron, Professor of Medicine at University of North Carolina (UNC) about the topic of his upcoming presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025: HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025. Dr Eron discusses the state of HIV cure research including a detailed discussion of why it has been so difficult to develop a cure for HIV. Dr Saag and Dr Eron discuss the difference between HIV cure and functional cure and provide a detailed overview of cure research efforts looking at blocking and locking HIV in human DNA. Dr Saag and Dr Eron also discuss the potential for “molecular scissors” (CRISPR-Cas9) to cure HIV. Finally, they provide an overview of cure research that will be presented at CROI, highlighting the plenary presentation by Dr Ole Søgaard at CROI on Monday March 10 entitled HIV Cure: A Translational Research Perspective. For more information about the topic of this episode, listen to an earlier episode of Going anti-Viral where Dr Saag discusses Vaccine Development with Dr Richard Koup, see links in the resources below. 0:00 – Introduction1:31 – Defining cure in the context of HIV4:56  – Why is it so hard to cure HIV7:56 – What is functional cure11:47 – Description of the concept of “block and lock” in human DNA14:33 – Discussion of tat inhibitors – blocking of HIV regulatory genes18:02 – Prospect of using “molecular scissors” (CRISPR-Cas9) as a cure23:13 – Highlights in HIV cure research at CROI and closing remarksResources: CROI 2025: https://www.croiconference.org/Going anti-Viral Episode 4 – A Deep Dive into Vaccine Development with Dr Richard Koup: Apple Podcasts: https://podcasts.apple.com/us/podcast/episode-4-a-deep-dive-into-vaccine-development-with/id1713226144?i=1000637677124 YouTube: https://youtu.be/nXeMt3GMj4Q __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

CardioNerds Cardiac Amyloidosis Series Chair Dr. Rick Ferraro and Episode Lead Dr. Anna Radakrishnan discuss the biology of transthyretin amyloid cardiomyopathy (ATTR-CM ) with Dr. Daniel Judge.  Notes were drafted by Dr. Anna Radakrishnan. The audio was engineered by student Dr. Julia Marques.  This episode provides a comprehensive overview of transthyretin (ATTR) cardiac amyloidosis, a complex and rapidly evolving disease process. The discussion covers the key red flags for cardiac amyloidosis, the diagnostic pathway, and the implications of hereditary versus wild-type ATTR. Importantly, the episode delves into the current and emerging therapies for ATTR, including stabilizers, gene silencers, and promising treatments like CRISPR-Cas9 and antibody-based approaches. Dr. Judge shares his insights and excitement about the rapidly advancing field, highlighting the need for early diagnosis and the potential to improve long-term outcomes for patients with this condition.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.  CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: - Biology of Transthyretin amyloid cardiomyopathy Maintain a high index of suspicion! Look for subtle (yet telling) signs like ventricular hypertrophy, discordant EKG findings, bilateral carpal tunnel syndrome, and spontaneous biceps tendon rupture.  Utilize the right diagnostic tests. Endomyocardial biopsy remains the gold standard, but non-invasive tools like PYP scan with SPECT imaging and genetic testing are essential for accurate diagnosis.  Differentiating hereditary from wild-type ATTR is critical, as genetic forms may have a more aggressive course and familial implications.  Early diagnosis and intervention significantly improve prognosis, making vigilance in screening and prompt treatment initiation essential.  The future is now! Cutting-edge therapies are transforming the treatment landscape, including TTR stabilizers, gene silencers, and emerging technologies like CRISPR-Cas9 and antibody-based treatments.  Notes - Biology of Transthyretin amyloid cardiomyopathy What is transthyretin amyloid (aTTR) and how is it derived?  Transthyretin (TTR) is a transport protein primarily synthesized by the liver, responsible for carrying thyroid hormones (thyroxine) and retinol (vitamin A) in the blood. It circulates as a tetramer, composed of four identical monomers, which is essential for its stability and function.  In transthyretin amyloid (ATTR) amyloidosis, the TTR protein becomes unstable, leading to its dissociation into monomers. These monomers misfold and aggregate into insoluble amyloid fibrils, which deposit extracellularly in tissues such as the heart, nerves, and gastrointestinal tract. This progressive amyloid deposition leads to organ dysfunction, including restrictive cardiomyopathy and neuropathy.  There are two main forms of ATTR amyloidosis: hereditary (variant) and wild-type (senile) ATTR.  Hereditary ATTR (ATTRv) is caused by mutations in the TTR gene. These mutations destabilize the TTR tetramer, making it more prone to dissociation. This increases misfolding and amyloid fibril formation, resulting in systemic amyloid deposition.   Wild-type ATTR (ATTRwt) occurs without genetic mutations and is primarily age-related. Over time, even normal TTR tetramers can become unstable, leading to gradual misfolding and amyloid deposition, particularly in the heart. ATTRwt is a common but often underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in elderly individuals.  How does aTTR lead to deleterious effects in the heart and other organ systems?    Transthyretin amyloidosis leads to organ dysfunction through the deposition of misfolded TTR protein as amyloid fib...

The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the latest BioCentury This Week podcast, BioCentury's editors discuss the lessons learned by this small group of companies since their launch a decade ago. They also discuss the entrance of AbbVie into the obesity race via a $350 million deal with Gubra for a clinical stage amylin agonist — does it signal AbbVie's belief in amylin monotherapy, or will the company be hunting for more obesity assets? The editors also talk about recommendations to streamline the early-stage development of rare disease therapies in the U.S.View full story: https://www.biocentury.com/article/65521400:00 - Introduction00:36 - CRISPR Companies09:22 - AbbVie Enters Obesity Race17:19 - Rare Disease Drug ChallengesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

‘Masterclass' a cargo del científico del Centro Nacional de Biotecnología (CBN) y divulgador Lluis Montoliu sobre la investigación y el diagnóstico de enfermedades raras. Además, y para empezar, Montoliu explica cómo científicos japoneses han logrado eliminar con técnicas CRISPR-Cas9 la tercera copia del ‘Cromosoma 21', que provoca el síndrome de Down. De momento, lo han conseguido in-vitro. 

‘Masterclass' a cargo del científico del Centro Nacional de Biotecnología (CBN) y divulgador Lluis Montoliu sobre la investigación y el diagnóstico de enfermedades raras. Además, y para empezar, Montoliu explica cómo científicos japoneses han logrado eliminar con técnicas CRISPR-Cas9 la tercera copia del ‘Cromosoma 21', que provoca el síndrome de Down. De momento, lo han conseguido in-vitro. 

À l'heure de l'intelligence artificielle, le transhumanisme, qui prône l'usage des sciences afin d'améliorer la condition humaine par l'augmentation de ses capacités physiques et mentales, se développe dans l'ombre. En 2012, les chercheuses Emmanuelle Charpentier et Jennifer Doudna, prix Nobel de chimie 2020, ont créé un système de modification du génome humain, rapide et peu coûteux. Leur technique, appelée CRISPR-Cas9, a été créée dans le but d'aider à lutter contre les maladies génétiques. Mais derrière la prouesse d'une telle technologie se sont des questions éthiques reviennent. En effet, les questionnement autour l'idéologie eugéniste reviennent sur de la scène, il s'agit de la sélection du patrimoine génétique des générations futures d'une population en fonction d'un cadre de choisi.  D'où vient l'eugénisme ? Pourquoi parle-t-on d'eugénisme positif ? Pourquoi ce concept est-il d'actualité ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Samuel Lumbroso. À écouter aussi : Qu'est-ce que le racisme environnemental ? Quel est ce mouvement qui fait participer les amateurs à la science ? Que risque-t-on à devenir volontaire pour la science ? Retrouvez tous les épisodes de "Maintenant vous savez". Première diffusion le 14/07/23 Learn more about your ad choices. Visit megaphone.fm/adchoices

Sorti en 1997 et réalisé par Andrew Niccol, "Bienvenue à Gattaca" (Gattaca en version originale) est considéré par la NASA comme le film de science-fiction le plus réaliste de tous les temps. Cette distinction repose sur la plausibilité scientifique du scénario, qui aborde un futur où le génie génétique joue un rôle central dans la société humaine. Contrairement à d'autres films de science-fiction centrés sur des technologies lointaines ou futuristes, "Bienvenue à Gattaca" explore des avancées qui pourraient devenir réalité dans un avenir proche.L'intrigue du film se déroule dans un monde où les enfants sont conçus en laboratoire, permettant aux parents de choisir les caractéristiques génétiques idéales pour garantir la santé, l'intelligence et les aptitudes physiques optimales. Ceux qui naissent de manière naturelle, sans intervention génétique, sont désavantagés et subissent une discrimination institutionnalisée. Le personnage principal, Vincent Freeman, est un "invalide", c'est-à-dire un individu né sans sélection génétique, qui rêve d'intégrer Gattaca, une prestigieuse institution spatiale. Pour contourner les barrières génétiques, il usurpe l'identité d'un individu génétiquement "supérieur", soulevant ainsi des questions éthiques fondamentales sur le déterminisme génétique et le libre arbitre.Ce que la NASA a particulièrement apprécié dans "Bienvenue à Gattaca", c'est son approche réaliste des avancées en biotechnologie et en eugénisme. Avec les progrès actuels dans la manipulation du génome humain, comme la technologie CRISPR-Cas9, il est désormais envisageable de modifier l'ADN pour prévenir certaines maladies héréditaires et optimiser les caractéristiques humaines. Le film soulève des préoccupations sur l'émergence potentielle d'une société divisée entre "génétiquement privilégiés" et "naturels", ce qui résonne fortement avec les débats bioéthiques actuels.En plus de son réalisme scientifique, le film se distingue par son atmosphère épurée et son style rétro-futuriste, mettant en avant une vision dystopique où les progrès scientifiques conduisent à de nouvelles formes de discrimination. L'absence de technologies extravagantes renforce l'impression que ce futur est à portée de main, rendant le récit d'autant plus crédible.En conclusion, "Bienvenue à Gattaca" offre une réflexion percutante sur les dérives possibles du génie génétique, en s'appuyant sur des fondements scientifiques solides. Sa reconnaissance par la NASA témoigne de la pertinence de ses questionnements et de sa capacité à anticiper les défis éthiques et sociaux liés aux avancées biotechnologiques modernes. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Join CardioNerds Heart Failure Section Chair Dr. Jenna Skowronski, episode lead Dr. Apoorva Gangavelli, and expert faculty Dr. Ronald Witteles as they discuss the Nex-Z trial. This was a phase 1, open-label trial investigating nex-z, a CRISPR-Cas9-based treatment, in 36 patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The primary objectives were aimed at studying the safety and pharmacodynamics of this novel gene-based treatment modality. This episode dives into the nuances of the data, future directions for investigation, and future clinical implications. CardioNerds Journal Club PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References - The Nex-Z Trial Fontana, M., Solomon, S. D., Kachadourian, J., Walsh, L., Rocha, R., Lebwohl, D., Smith, D., Täubel, J., Gane, E. J., Pilebro, B., Adams, D., Razvi, Y., Olbertz, J., Haagensen, A., Zhu, P., Xu, Y., Leung, A., Sonderfan, A., Gutstein, D. E., & Gillmore, J. D. (2024). CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2412309

2025 promises to be another busy year for intellectual property law. In this episode of IP Talk with Wolf Greenfield, you'll hear Wolf Greenfield attorneys from a variety of practice areas reviewing some of the top issues of 2024 and offering their insights on what to expect in the months ahead. Here are some of the highlights:01:02 - Chelsea Loughran's thoughts on The University of California v. Broad Institute, a federal court case involving competing patent applications for the CRISPR-Cas9 gene-editing system02:25 - Zach Piccolomini is watching the Unified Patent Court (UPC) for upcoming decisions in the standard essential patent space and “fair, reasonable and non-discriminatory” royalties03:34 - Jonathan Roses with insight on recent Orange Book developments and what to expect with the new administration  05:31 - Jen Wang offers advice for dealing with rejections in the wake of the Federal Circuit overturning a 40-year-old obviousness test for design patents in the LKQ v. GM case06:34 - Scott McKeown on noteworthy 2024 developments at the USPTO and some thoughts for what might happen in 2025 08:43 - John Strand on the Dewberry case, which was just argued before the Supreme Court (a decision is expected in the spring)10:23 - Gabe McCool discusses the BIO Secure Act  

Emmanuelle Charpentier has received the Nobel Prize in Chemistry for discovering genetic scissors –– CRISPR/Cas9. She was the head of the jury of the ESET Science Award and gave a lecture for students during the ESET4Schools event. So did Samuel, so they have got some time to discuss a little. Has the name CRISPR/Cas9 stuck or can we change it to something simpler? Will gene modifications change humankind in the next century? How to become a good scientist? This and much more have been asked by Samuel. Na Youtube nájdete epizódu s (automatickými) titulkami.  Máme novú knihu – Rozhovory o vesmíre https://www.martinus.sk/2901887-rozhovory-o-vesmire/kniha Podcastové hrnčeky a ponožky nájdete na stránke https://vedator.space/vedastore/ Vedátora môžete podporiť cez stránku Patreon https://www.patreon.com/Vedator_sk   Všetko ostatné nájdete tu https://linktr.ee/vedatorsk Vedátorský newsletter http://eepurl.com/gIm1y5

Imaginez pouvoir utiliser l'ADN, le support fondamental de l'information génétique de tous les êtres vivants, pour stocker des données numériques. C'est exactement ce que des scientifiques ont réalisé, et c'est fascinant ! Le 12 juillet 2017, une étude publiée dans Nature a révélé que des chercheurs ont réussi à encoder et stocker un GIF — une série d'images animées — dans l'ADN de Escherichia coli, une bactérie intestinale commune. D'abord, rappelons que l'ADN est un polymère constitué de quatre bases azotées : adénine (A), thymine (T), cytosine (C) et guanine (G). Ces quatre "lettres" forment un code très dense qui peut contenir des quantités massives d'informations. Si l'on pense à l'ADN comme à un langage, les chercheurs ont trouvé un moyen de convertir des données numériques, comme les pixels d'une image ou les images d'un GIF, en ce langage biologique. Pour ce faire, ils ont utilisé la technologie CRISPR-Cas9, connue pour ses capacités d'édition génomique de haute précision. CRISPR agit comme des "ciseaux moléculaires" capables d'insérer des séquences d'ADN de manière spécifique dans le génome d'une cellule. Dans cette expérience, les scientifiques ont traduit chaque pixel du GIF en une séquence de bases A, T, C, et G, qu'ils ont ensuite insérée dans l'ADN de la bactérie. CRISPR a permis d'encoder ces données image par image, de manière séquentielle, dans le génome des cellules de E. coli. Le GIF choisi pour cette expérience était un extrait historique d'une série d'images d'un cheval au galop, créé par Eadweard Muybridge, une référence aux débuts du cinéma. Une fois le GIF encodé dans l'ADN des bactéries, celles-ci se sont reproduites, transmettant ces informations génétiques à leurs descendants. Pour vérifier si le stockage avait fonctionné, les chercheurs ont séquencé l'ADN des bactéries, récupéré les données, et reconstitué l'image animée. Résultat : le GIF a pu être reconstitué, montrant que l'ADN avait fidèlement stocké et protégé ces données. Ce travail est révolutionnaire parce qu'il démontre le potentiel de l'ADN comme support de stockage de données extrêmement dense et stable. Un gramme d'ADN peut théoriquement contenir 215 millions de gigaoctets d'information ! L'ADN ne se dégrade que très lentement dans des conditions favorables, ce qui en fait un moyen prometteur pour l'archivage de données à long terme. Ce type de recherche ouvre des perspectives passionnantes pour l'avenir, où la biologie pourrait s'entremêler avec la technologie de l'information de manière encore plus impressionnante. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Did you miss AHA 2024? Listen here to brief discussions of the latest research. Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMe2414473.

Alžběta Ressnerová je genová inženýrka, která byla na stáži v prestižní laboratoři Berkeley v Kalifornii. Zde metodou CRISPR-Cas9, také zvanou genetické nůžky, zkoumá, jakým způsobem dopravit opravené buňky na správné místo v těle člověka. Ressnerová si myslí, že takto půjde uzdravit nevyléčitelně nemocné. „V ideálním případě by CRISPR pomáhal zachraňovat životy bez ohledu na sociální postavení,“ doufá vědkyně. Jak se staví k etické otázce upravování genů?

Drive with Dr. Peter Attia: Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Feng Zhang, a professor of neuroscience at MIT and a pioneering figure in gene editing, joins Peter to discuss his groundbreaking work in CRISPR technology, as well as his early contributions to optogenetics. In this episode, they explore the origins of CRISPR and the revolutionary advancements that have transformed the field of gene editing. Feng delves into the practical applications of CRISPR for treating genetic diseases, the importance of delivery methods, and the current successes and challenges in targeting cells specific tissues such as those in the liver and eye. He also covers the ethical implications of gene editing, including the debate around germline modification, as well as reflections on Feng's personal journey, the impact of mentorship, and the future potential of genetic medicine. We discuss: Feng's background, experience in developing optogenetics, and his shift toward improving gene-editing technologies [2:45]; The discovery of CRISPR in bacterial DNA and the realization that these sequences could be harnessed for gene editing [10:45]; How the CRISPR system fights off viral infections and the role of the Cas9 enzyme and PAM sequence [21:00]; The limitations of earlier gene-editing technologies prior to CRISPR [28:15]; How CRISPR revolutionized the field of gene editing, potential applications, and ongoing challenges [36:45]; CRISPR's potential in treating genetic diseases and the challenges of effective delivery [48:00]; How CRISPR is used to treat sickle cell anemia [53:15]; Gene editing with base editing, the role of AI in protein engineering, and challenges of delivery to the right cells [1:00:15]; How CRISPR is advancing scientific research by fast-tracking the development of transgenic mice [1:06:45]; Advantages of Cas13's ability to direct CRISPR to cleave RNA and the advances and remaining challenges of delivery [1:11:00]; CRISPR-Cas9: therapeutic applications in the liver and the eye [1:19:45]; The ethical implications of gene editing, the debate around germline modification, regulation, and more [1:30:45]; Genetic engineering to enhance human traits: challenges, trade-offs, and ethical concerns [1:40:45]; Feng's early life, the influence of the American education system, and the critical role teachers played in shaping his desire to explore gene-editing technology [1:46:00]; Feng's optimism about the trajectory of science [1:58:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Drive with Dr. Peter Attia Key Takeaways The human genome was sequenced 25 years ago, what's the delay in editing? We know the sequence of the genes but we don't know what most of the genes do, nor do we fully understand the coding and non-coding sequence (yet)CRISPR is an adaptive immune system: After the first infection, the bacteria has been ‘vaccinated' against the virus The next time the virus comes around, it will inject its genetic information into the bacteria but now the bacteria in the CRISPR area have a signature of the virusDifficulties in application of CRISPR: CRISPR uses a guide RNA to recognize the virus DNA but delivery of the Cas + guide RNA needs to be precise and the protein is too large to insert with ease But, solving the delivery issue doesn't mean CRISPR is suitable for all diseases; its most potent application is for genetic mutations (and likely not cancer which has many different mutations in the cell)Future goals of CRISPR technology: Creating more feasible Cas and guide RNA delivery system; inserting large genes into the genome, precisely and efficientlyEthical considerations of gene editing germline: Slippery slope argument: If we allow X and Y, we will enter an unchartered territory with designer babies, making babies smarter (which we don't know how to do), etc. It's worth noting that athletics, and intelligence, are more complicated than we want to believe; even with the right genetics, environment plays a huge role in realizing genesThinking about how the line should be drawn: Is there an obvious and important medical benefit?Read the full notes @ podcastnotes.org View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Feng Zhang, a professor of neuroscience at MIT and a pioneering figure in gene editing, joins Peter to discuss his groundbreaking work in CRISPR technology, as well as his early contributions to optogenetics. In this episode, they explore the origins of CRISPR and the revolutionary advancements that have transformed the field of gene editing. Feng delves into the practical applications of CRISPR for treating genetic diseases, the importance of delivery methods, and the current successes and challenges in targeting cells specific tissues such as those in the liver and eye. He also covers the ethical implications of gene editing, including the debate around germline modification, as well as reflections on Feng's personal journey, the impact of mentorship, and the future potential of genetic medicine. We discuss: Feng's background, experience in developing optogenetics, and his shift toward improving gene-editing technologies [2:45]; The discovery of CRISPR in bacterial DNA and the realization that these sequences could be harnessed for gene editing [10:45]; How the CRISPR system fights off viral infections and the role of the Cas9 enzyme and PAM sequence [21:00]; The limitations of earlier gene-editing technologies prior to CRISPR [28:15]; How CRISPR revolutionized the field of gene editing, potential applications, and ongoing challenges [36:45]; CRISPR's potential in treating genetic diseases and the challenges of effective delivery [48:00]; How CRISPR is used to treat sickle cell anemia [53:15]; Gene editing with base editing, the role of AI in protein engineering, and challenges of delivery to the right cells [1:00:15]; How CRISPR is advancing scientific research by fast-tracking the development of transgenic mice [1:06:45]; Advantages of Cas13's ability to direct CRISPR to cleave RNA and the advances and remaining challenges of delivery [1:11:00]; CRISPR-Cas9: therapeutic applications in the liver and the eye [1:19:45]; The ethical implications of gene editing, the debate around germline modification, regulation, and more [1:30:45]; Genetic engineering to enhance human traits: challenges, trade-offs, and ethical concerns [1:40:45]; Feng's early life, the influence of the American education system, and the critical role teachers played in shaping his desire to explore gene-editing technology [1:46:00]; Feng's optimism about the trajectory of science [1:58:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Feng Zhang, a professor of neuroscience at MIT and a pioneering figure in gene editing, joins Peter to discuss his groundbreaking work in CRISPR technology, as well as his early contributions to optogenetics. In this episode, they explore the origins of CRISPR and the revolutionary advancements that have transformed the field of gene editing. Feng delves into the practical applications of CRISPR for treating genetic diseases, the importance of delivery methods, and the current successes and challenges in targeting cells specific tissues such as those in the liver and eye. He also covers the ethical implications of gene editing, including the debate around germline modification, as well as reflections on Feng's personal journey, the impact of mentorship, and the future potential of genetic medicine. We discuss: Feng's background, experience in developing optogenetics, and his shift toward improving gene-editing technologies [2:45]; The discovery of CRISPR in bacterial DNA and the realization that these sequences could be harnessed for gene editing [10:45]; How the CRISPR system fights off viral infections and the role of the Cas9 enzyme and PAM sequence [21:00]; The limitations of earlier gene-editing technologies prior to CRISPR [28:15]; How CRISPR revolutionized the field of gene editing, potential applications, and ongoing challenges [36:45]; CRISPR's potential in treating genetic diseases and the challenges of effective delivery [48:00]; How CRISPR is used to treat sickle cell anemia [53:15]; Gene editing with base editing, the role of AI in protein engineering, and challenges of delivery to the right cells [1:00:15]; How CRISPR is advancing scientific research by fast-tracking the development of transgenic mice [1:06:45]; Advantages of Cas13's ability to direct CRISPR to cleave RNA and the advances and remaining challenges of delivery [1:11:00]; CRISPR-Cas9: therapeutic applications in the liver and the eye [1:19:45]; The ethical implications of gene editing, the debate around germline modification, regulation, and more [1:30:45]; Genetic engineering to enhance human traits: challenges, trade-offs, and ethical concerns [1:40:45]; Feng's early life, the influence of the American education system, and the critical role teachers played in shaping his desire to explore gene-editing technology [1:46:00]; Feng's optimism about the trajectory of science [1:58:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Ficha técnica Hosts: Leticia Dáquer e Thiago Corrêa  Edição: Leticia Dáquer Capa: Leticia Dáquer Data da gravação: 20/10/2024 Data da publicação: 24/10/2024   Músicas/áudios: The Oldest Song in the World The Most Mysterious Song on the Internet - HQ Stereo Remastered   Coisas mencionadas no episódio: Episódio do Stuff You Should Know sobre mistérios da internet, incluindo a música desconhecida Música da bunda do Bosch A música mais misteriosa da internet (Wikipedia) But what is CRISPR-Cas9? An animated introduction to Gene Editing   Bom Leticia World-first therapy using donor cells sends autoimmune diseases into remission (Nature, 04/10/2024) Discovering Roman mosaics - A fabulous new find where history meets luxury in Antakya (World Archeology, 18/11/2020) Thiago Ouça a música mais antiga do mundo, de 3.400 anos (Olhar Digital, 29/07/2024) World's first ‘meltdown-proof' nuclear reactor aces safety test (New Atlas, 24/07/2024) Brazilian artist swaps historical coin in British Museum for a fake (The Guardian, 22/07/2024)   Mau Leticia Políticos de cidade alemã querem restringir venda de kebab (Carta Capital, 12/08/2024) Thiago  Music industry's 1990s hard drives, like all HDDs, are dying (12/09/2024)   Feio Leticia State-of-the-Art Fire Station Leveled by Blaze (Newsweek, 18/10/2024) Woman passes her driving test on her 960th go after spending £11,000 (The Mirror, 26/03/2023) Comandante de navio dos EUA é rebaixado após atirar com a mira ao contrário (UOL, 04/09/2024) Engenheira mantém 7,4 mil abas abertas no Firefox há mais de dois anos (Terra, 07/05/2024) Two San Francisco nudists save man from being attacked in street by a "crazy kind of pirate guy"with a blowtorch (MSN, 07/2024) Thiago Alemanha vai parar de usar disquetes em navios de guerra (Tecnoblog, 07/2024) MS-DOS and Windows 3.11 still run train dashboards at German railway — company listed admin job for 30-year-old operating system (Tom's Hardware, 29/01/2024) Math student builds fusion reactor at home with help from Claude AI and $2,000 (Techspot, 03/09/2024) Restaurant sues customer over $3,000 waitress tip he left on $13 meal (Unilad, 01/07/2024) Maldives minister arrested for performing ‘black magic' on President Muizzu: Report (Hindustan Times, 28/06/2024)   Parceria com Veste Esquerda: Agora tem camiseta do Pistolando direto no site da Veste Esquerda! Mas o código de desconto PISTOLA10 dá 10% de desconto na sua compra da nossa e de outras camisetas maneiríssimas esquerdopatas!   Parceria com Editora Boitempo: compre livros por esse link aqui pra gente ganhar uns trocados de comissão :)   Nosso link de associados da Amazon, mas só em último caso, hein: bit.ly/Pistolando    Parceria com o ICL: inscreva-se nos cursos pelo nosso link   Esse podcast é produzido pelo Estopim Podcasts. Precisa de ajuda pra fazer o seu podcast? Chega mais, que a gente te dá uma mãozinha.     Links do Pistolando www.pistolando.com contato@pistolando.com Twitter: @PistolandoPod Instagram: @PistolandoPod   Apóie o Pistolando no Catarse, no Patreon e agora também no PicPay, ou faça um Pix pra gente usando a chave contato@pistolando.com   Descrição da capa:  

durée : 00:05:28 - Avec sciences - par : Alexandra Delbot - La xénotransplantation est une technique de greffe d'organes provenant d'animaux. Grâce à l'avènement des ciseaux moléculaires CRISPR-Cas9, les risques de rejet suraigu sont considérablement réduits. Où en est la recherche actuellement ? Quels sont les enjeux éthiques de la xénogreffe ?

As the global population approaches 10 billion by 2050, the challenge of providing safe, nutritious food is growing more urgent. Climate change is further straining food systems, impacting water availability, crop yields, and livestock health. In this episode, two experts discuss innovative biotech solutions aimed at addressing these pressing issues, offering hope for a sustainable path forward in feeding the world.Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

Comenzamos la segunda hora de Poniendo las Calles y lo hacemos con una historia muy inspiradora. Y también hablamos de genética y de lo que esconde tanto la medicina personalizada como lo que nos permite hacer la Tecnología CRISPR-Cas9 de la mano de Sergio Parra, el coordinador de Genoma.

CRISPR-Cas9 gene editing technology is one of the newest and most promising tools in science. But what is it? How does it work? And what are scientists doing with this technology that has been described as a molecular genetic scalpel? In this first of two episodes, we talk with Dr. Rodolphe Barrangou, the first scientist to discover and publish results demonstrating what the CRISPR-Cas9 system can do, thereby opening the door for other scientists and discoveries.

In this episode, Prof Michael Chapman, discusses the world of gene editing. He explores the groundbreaking potential of CRISPR Cas9, a tool that could revolutionize the way we address genetic diseases. Prof. Chapman discusses the ethical dilemmas highlighted by controversial experiments, as well as the future implications of these advancements. He also touches on the role of epigenetic testing in IVF treatments and its potential to enhance reproductive success.  Join us for an insightful conversation on the science and ethics of gene editing. Explore the 'Prof. Michael Chapman - The IVF Journey' Facebook Page, your reliable destination for cutting-edge insights and guidance within the realm of In Vitro Fertilization (IVF). Don't miss out on the IVF Journey podcast; stay informed with the latest episode updates. Tune in for expert discussions and valuable information on navigating the intricate path of IVF.

Menschen spekulieren an der Börse. Warum tun sie das? Weil sie schnell reich werden möchten! Ist das etwas Verwerfliches? Nein, das ist es nicht. Allerdings ist die Gefahr Geld zu verlieren relativ hoch. Worauf man daher also achten sollte, welches Potential aber auch die Branchen und die Entwicklungen haben, die wirklich die Welt verändern: Darüber möchte ich heute im Podcast reden.
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Den neuen Podcast “Buy The Dip” findet ihr hier: https://buythedip.podigee.io
 ► Schau Dir hier die neue Aktion der Rendite-Spezialisten an: https://www.rendite-spezialisten.de/aktion
 ► TIPP: Sichere Dir wöchentlich meine Tipps zu Gold, Aktien, ETFs & Co. – 100% gratis: https://erichsen-report.de/
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Quelle der Audio-Snippets, abgerufen am 17.07.2024:
 URL: https://www.youtube.com/watch?v=cO-2NAl7Sm0 Titel: One more thing ... YouTube-Kanal: All About Steve Jobs
 URL: https://www.youtube.com/watch?v=ZwiKaz0kr24 Titel: Projekt U-Bahn 100 startet Testphase YouTube-Kanal: Hamburg 1 Fernsehen
 URL: https://www.youtube.com/watch?v=ouXrsr7U8WI Titel: Gen-editing mit CRISPR/Cas9 (english subtitles) YouTube-Kanal: MaxPlanckSociety
 URL: https://www.youtube.com/watch?v=kPd56OY2ED8 Titel: Richard Branson Speaks on Plan for Space Tourism YouTube-Kanal: Smithsonian Channel
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
 Sound-Effekte stammten von: applause.wav by thedapperdan -- https://freesound.org/s/26807/ -- License: Creative Commons 0
 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Offenlegung wegen möglicher Interessenkonflikte: Die Autoren sind in den folgenden besprochenen Wertpapieren bzw. Basiswerten zum Zeitpunkt der Veröffentlichung investiert: -

In this episode, Buck discusses gene editing and its potential implications for human health and longevity. He explains the basics of gene editing, including the structure of DNA and how genes are transcribed into proteins, then dives into the history and development of gene editing techniques, focusing on the game-changing CRISPR-Cas9 technology. He also explores the practical applications of gene editing, such as its use in treating sickle cell anemia and other genetic diseases, as well as the potential for human longevity, including targeting genes associated with aging and reversing epigenetic age.

För 50 år sen lärde sig forskare att flytta gener mellan olika organismer. Då visste ingen vart gentekniken skulle leda. Idag växer GMO-grödor på många åkrar - medan frågetecken kvarstår i medicinen. Lyssna på alla avsnitt i Sveriges Radio Play. De första försöken med att förse bakterier med nya gener som kom från virus gjordes i början av 1970-talet. Farhågor uppstod snart kring riskerna. Skulle de nya transgena bakterierna kunna leda till en smittsam form av cancer, eller andra nya okända biologiska faror?Frågan gjorde att forskarna frivilligt gjorde en paus för att reda ut hur farlig den nya gentekniken var.Arbetet med de nya gentekniska verktygen kom snart igång igen, men nu omgärdade av en rad strikta säkerhetsåtgärder som många gånger gäller än idag, för att genförändrade växter eller bakterier inte okontrollerat ska slippa ut i omgivningen.När gensaxen Crispr/Cas9 presenterades 2012 kom nya möjligheter, och diskussionen tog fart igen – inte minst om vad man ska få göra med mänskliga gener som går i arv.I programmet medverkar genetikerna Magnus Lundgren, Uppsala universitet och Juha Kere från Karolinska Institutet, samt Niklas Juth som är professor i medicinsk etik i Uppsala.Programmet är en repris från februari 2024. Programledare: Tomas LindbladProducent: Camilla Widebeckcamilla.widebeck@sverigesradio.se

We love to hear from our listeners. Send us a message.KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. In addition to solid tumors, Benson also addresses the therapeutic potential for autoimmune disease.

Welcome to the inaugural episode of the Two Bears Podcast! In this episode of "Two Bears Podcast," Chef Zev Bennett & Chef Don Splain discuss their culinary journeys and experiences. Chef Don shares some of his Native American heritage and early cooking memories. Chef Zev Bennett recounts his childhood fascination with cookbooks while growing up in an Orthodox Jewish household. They explore their paths into the culinary world, including pivotal moments like Chef Zev's change in education tract from studying CRISPR-Cas9 to culinary school in Thailand. The conversation touches on the influence of culinary legends like Escoffier and the impact of African American culture on American cuisine.

TAKEAWAYSPeople who take the mark of the beast during the End Times will likely be genetically altered in some wayHuman depopulation is the top goal of the global elites who are working for LuciferAt some point, the military powers of the world will answer to the Antichrist, whom Scott believes will be a NephilimGod's wrath is coming for those who have broken his everlasting covenant with mankind

TWiV reviews viruses in the news: Chinese scientist who released the SARS-CoV-2 genome sequence sleeps in the street, a case of measles in Haifa, spread of waterborne infectious diseases in Gaza, interstate spread of avian influenza A(H5N1) in dairy cattle, and an orangutan heals himself with medicinal plants, followed by identification of a cell receptor for parechoviruses, and blockade of necroptosis prevents lung injury in severe influenza. Hosts: Vincent Racaniello, Dickson Despommier, and Alan Dove Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Become a member of ASV (asv.org) The New City by Dickson Despommier (blog post) International Conference on Pandemic Preparedness Chinese virologist sleeps on street (Nature) Measles in Haifa (Jerusalem Post) Waterborne illness spreads in Gaza (Reuters) Interstate spread of H5N1 virus in dairy cattle (bioRxiv) Orangutan uses medicinal plants (Science) Parechovirus cell receptor identified (Nat Comm) Necroptosis blockade prevents lung injury in influenza (Nature) Necroptosis, pyroptosis and apoptosis (Cell Mol Immunol) Letters read on TWiV 1111 Timestamps by Jolene. Thanks! Weekly Picks Dickson – NASA's Webb Finds Ethanol, Other Icy Ingredients for Worlds Alan – MyClimate.org calculators Vincent – Twenty-Five Lectures in Virology 2024 Listener Picks Alan – NPR story and interactive quiz on pandemic respiratory disease transmission Az – H5N1 Avian Flu in Mammals Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

durée : 00:03:34 - Un monde connecté - par : François Saltiel - Utiliser la manipulation génétique pour contrer les menaces écologiques, c'est l'objectif de certains chercheurs qui proposent d'utiliser l'outil de modification du génome CRISPR-Cas9. Cependant, ces avancées soulèvent des préoccupations éthiques et environnementales.

BestPodcastintheMetaverse.com Canary Cry News Talk #727 03.27.2024 - Recorded Live to 1s and 0s THREAT CRAFTING | Bridge False Flags, Cancer CRISPR, Ice Turf War Deconstructing Corporate Mainstream Media News from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! TJT Youtube (backup) Channel: https://www.youtube.com/@TheJoyspiracyTheory The Show Operates on the Value 4 Value Model: http://CanaryCry.Support Join the Supply Drop: https://CanaryCrySupplyDrop.com                   Submit Articles: https://CanaryCry.Report Submit Art: https://CanaryCry.Art Join the T-Shirt Council: https://CanaryCryTShirtCouncil.com Podcasting 2.0: https://PodcastIndex.org Resource: Index of MSM Ownership (Harvard.edu)             Resource: Aliens Demons Doc (feat. Dr. Heiser, Unseen Realm) Resource: False Christ: Will the Antichrist Claim to be the Jewish Messiah Tree of Links: https://CanaryCry.Party   This Episode was Produced By: Executive Producers Sir LX Protocol V2 Knight of the Berrean Protocol*** Felicia D***   Producers of Treasure Sir Marti K Knight of the Wrong Timeline Elle O Sir Darrin Knight of the Hungry Panda's Dame Gail Veronica D Misses TinFoilHatMan Sir Tristan Knight of the Garden Sir Morv Knight of the Burning Chariots Sir Casey the Shield Knight DrWhoDunDat Sir Scott Knight of Truth Sir Darrin Knight of the Hungry Panda's   Speakpipe Sir Ike   CanaryCry.ART Submissions Sir Dove Knight of Rusbeltia JonathanF Cassius S Sir Darrin Knight of the Hungry Panda's   MicroFictions Runksmash - The fiends begin to shake as the introduction plays, they stop fighting and untether themselves from the projectors, revealing their true demonic nature, but they can't escape before the name of Jesus escapes the speaker, and they are forced to flee.    Stephen S - With force cutbacks,  the Pittsville Police Department took on a pilot program from BuyMyTek.  A  chapGPT AI powered interactive voice response solution will replace their 911 emergency  dispatchers between the hours of midnight to 6 am.    JOLMS - Following the prolonged silence from the captain, the flight deck system (authority level 4), sends an emergency clearance request to any nearby level 3s. In the main deck, a metal compound purifier boots up at the request. Stupefied at what aid its purification could offer with such, it bounces off the requests to any level 2s and shuts down. The energy management system (level 3), also deflected the request to level 2 but granted temporary rights to the use of solar arrays. One hurdle down.   TIMESTAMPERS Jade Bouncerson, Morgan E   CanaryCry.Report Submissions JAM   REMINDERS Clankoniphius   SHOW NOTES/TIMESTAMPS Podcast = T - 4:25 from rumble HELLO, RUN DOWN 8:16 V / 3:51 P BBB/CYBERPANDEMIC 10:28 V / 6:03 P Baltimore bridge collapses; 6 presumed dead (AP) →Shipping CEO Angela Chao, Mitch McConnell's sister-in-law, was intoxicated when she drove into lake, sheriff's office says (MSN/CNN) Angela Chao connected to Baltimore group (X) Lori Allan asked Grok (X) Someone isn't so sure (X) *Presser from Synergy Marine Group, Dec 8, 2021 (SMG)   DAY JINGLE/V4V/EPs/TREASURE 48:49 V / 44:24 P   FLIPPY 1:11:27 V / 1:07:02 P Hamas blew off his arm, fellow IDF soldiers mistook him for enemy —now combat medic gets state-of-the art robotic prosthetic in NYC: ‘I will have a normal life' (NY Post)   CANCER/CRISPR/PSYOPS 1:30:07 V / 1:25:42 P Kate Middletons Cancer Diagnosis a trend (Vox) King Charles' and the princess' cancer diagnosis (People) → Charts show sharp rise in young adults getting cancer before 50 (Business Insider) Harvard 2022 cancer on the rise (news.Harvard) *A nanotechnology‐based CRISPR/Cas9 genome editing in cancer treatment (Phys.org) → 2023 Annual Threat Assessment for the Intelligence Community 2023  → 2024 Annual Threat Assessment for Intelligence Community   ANTARCTICA/CALLED IT 2:26:33 V / 2:22:08 P We can't freeze out Antarctica's national security consequences (The Hill/Opinion)   OUTRO 2:36:44 V / 2:32:19 P END

Joining host Chadi is the esteemed James LaBelle, MD, PhD, Associate Director of Pediatrics and Director of the Stem Cell and Cellular Therapy Program at the University of Chicago. Dr. LaBelle elucidates the complexities of sickle cell disease, unraveling the devastating impact it has on individuals. The episode delves into various treatments and approaches to combat this formidable disease, including bone marrow transplant and the groundbreaking use of CRISPR-Cas9 technology. LaBelle shares insights into the recent research breakthroughs, citing the remarkable research report published in the New England Journal of Medicine, showcasing the successful application of CRISPR-Cas9 for sickle cell disease. This episode serves as a gateway into the promising future of genetic therapies. Read Dr. LaBelle's publication on CRISPR-Cas9 in NEJM. https://www.nejm.org/doi/full/10.1056/NEJMoa2215643 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Is it possible to make any organism fully resistant to viral infections? According to new research using E. coli from the Harvard Medical School Department of Genetics, the answer seems to be yes…eventually! Today, we're joined by one of the lead researchers in this study, Akos Nyerges. Among many fascinating developments in the fields of genetic engineering and synthetic biology, he discusses the ability to modify existing organisms to achieve desired changes, the use of new DNA building blocks to create synthetic organisms, the most challenging regions of DNA to engineer, and what to expect in the near future. Press play to discover: How an organism can be genetically engineered to have a genetic ‘firewall' from natural viral infections The difference between synthetic genomics and genetic engineering Applications of CRISPR-Cas9 gene-editing technology   The use of genetically engineered organisms in novel drug development Tune in for the full conversation, visit Home | Church Lab (harvard.edu) to learn more about Harvard's Department of Genetics, and feel free to contact Nyerges via email: Akos_Nyerges@hms.harvard.edu. Take advantage of a 5% discount on Ekster accessories by using the code FINDINGGENIUS. Enhance your style and functionality with premium accessories. Visit bit.ly/3uiVX9R to explore latest collection. Episode also available on Apple Podcasts: http://apple.co/30PvU9C

Patrick Bet-David explains why the FDA has officially approved CRISPR gene editing as a treatment for Sickle Cell Disease, marking a historic milestone in medical science. The science behind CRISPR-Cas9, a revolutionary gene-editing tool has transformed biomedical research. Understand how it can precisely alter DNA to correct genetic defects, potentially treating a range of illnesses. As CRISPR technology advances, so does the debate over its ethical use. PBD also discusses the controversial topic of designer babies, examining the moral implications and potential societal impacts of gene editing for non-therapeutic purposes. Connect one-on-one with the right expert to get the answers you need with Minnect: https://bit.ly/3MC9IXE Get best-in-class business advice with Bet-David Consulting: https://bit.ly/40oUafz Visit VT.com for the latest news and insights from the world of politics, business and entertainment: https://bit.ly/472R3Mz Visit Valuetainment University for the best courses online for entrepreneurs: https://bit.ly/47gKVA0 Text “PODCAST” to 310-340-1132 to get the latest updates in real-time! SUBSCRIBE TO: ​⁠  @VALUETAINMENT   @PBDPodcast   @ValuetainmentShortClips   @vtsoscast   @VALUETAINMENTRUSSIAN   @ValuetainmentComedy   @bizdocpodcast   @BrandonAceto   @theunusualsuspectspodcast   @kvoncomedy  ​⁠ Want to be clear on your next 5 business moves? https://bit.ly/3Qzrj3m Join the channel to get exclusive access to perks: https://bit.ly/3Q9rSQL Download the podcasts on all your favorite platforms https://bit.ly/3sFAW4N Patrick Bet-David is the founder and CEO of Valuetainment Media. He is the author of the #1 Wall Street Journal Bestseller “Your Next Five Moves” (Simon & Schuster) and a father of 2 boys and 2 girls. He currently resides in Ft. Lauderdale, Florida. --- Support this podcast: https://podcasters.spotify.com/pod/show/valuetainment/support